As we previously reported, the Ontario Court of Appeal affirmed the lower court’s decision dismissing Apotex’s claims against Eli Lilly under the Ontario and English Statutes of Monopolies, Trademarks Act, and common law conspiracy relating to an olanzapine patent. Eli Lilly had successfully obtained an order of prohibition against Apotex relating to Canadian Patent No. 2,041,113, which was later found invalid in a decision involving Novopharm (affirmed on appeal).
On April 27, 2023, the Supreme Court of Canada dismissed Apotex’s application for leave to appeal.
Should you have any questions, please do not hesitate to contact a member of the Pharmaceutical Litigation Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
On December 23, 2023, the Federal Court of Appeal (FCA) held that it was an abuse of process for Apotex to raise invalidity in defending actions under the Patented Medicines (Notice of Compliance) Reg...Read More
In a decision dated January 24, 2024, Justice Pallotta allowed Novartis’ application, finding that Biogen and Samsung’s use of the trademark BYOOVIZ in association with an ophthalmologic drug violates...Read More
Federal Court of Appeal affirms Minister of Health reasonable in concluding successor second person was entitled to benefit of NOA served by predecessorOn February 13, 2024, the Federal Court of Appeal (FCA) dismissed Bayer and Regeneron’s appeal: Bayer Inc v BGP Pharma ULC (Viatris Canada), 2024 FCA 29.Read More